Juno Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 500

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $10.4B

Juno Therapeutics General Information

Description

Developer of cell-based novel immunotherapies intended to change the way cancer and other serious diseases are treated. The company is engaged in developing autologous cellular biologics as an answer to overcoming tumor evasion as well as programming T cells to recognize and attack cancer cells, enabling medical professionals to treat various types of cancer.

Contact Information

Website
www.junotherapeutics.com
Formerly Known As
FC Therapeutics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Therapeutic Devices
Acquirer
Celgene
Primary Office
  • 400 Dexter Avenue North
  • Suite 1200
  • Seattle, WA 98109
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Juno Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 06-Mar-2018 $10.4B 00.000 000.00 Completed Generating Revenue
7. Secondary Transaction - Open Market 01-Sep-2017 00000 00.000 00.000 Completed Generating Revenue
6. 2PO 14-Sep-2015 00.000 Completed Generating Revenue
5. PIPE 29-Jun-2015 000 00.000 0000 Completed Clinical Trials - Phase 2
4. IPO 19-Dec-2014 00000 00000 00.000 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 01-Aug-2014 00000 00000 00000 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 24-Apr-2014 $176M $183M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A1) 26-Dec-2013 $6.67M $6.67M Completed Product Development
To view Juno Therapeutics’s complete valuation and funding history, request access »

Juno Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A2 00,000,000 00.000000 00 00 00 00 00 00.000
Series A1 9,000,000 $0.000100 8% $1 $1 1x $1 2.27%
Series A 87,722,673 $0.000100 8% $1 $1 1x $1 22.15%
To view Juno Therapeutics’s complete cap table history, request access »

Juno Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cell-based novel immunotherapies intended to change the way cancer and other serious diseases are treated.
Biotechnology
Seattle, WA
500 As of 2020
00.000
00.00 0000-00-00
000000&0 00.000

000000

derit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur
0000000000000
South San Francisco, CA
000 As of 0000
00000
0.000 0000-00-00
00000000 00000

000000

lla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui
0000000000000
Houston, TX
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Juno Therapeutics Competitors (36)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Allogene Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
0000000 0000000000 Formerly VC-backed Houston, TX 00 00000 00000000000 00000
000000000 Formerly VC-backed Rockville, MD 000 00000 000000000 00000
0000 000000 Formerly VC-backed Santa Monica, CA 0000 00000 000000&0 00000
000000000 Formerly VC-backed Paris, France 000 00000 00000000 00000
You’re viewing 5 of 36 competitors. Get the full list »

Juno Therapeutics Patents

  • 478

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 31

    Granted

  • 68

    Pending

  • 000

    Expiring in next 12 mo

Juno Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022252220-A1 Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma Pending 29-Mar-2021
AU-2022241654-A1 Methods of determining potency of a therapeutic cell composition Pending 22-Mar-2021
AU-2022244229-A1 Method to assess potency of viral vector particles Pending 22-Mar-2021 000000000
CA-3208944-A1 Method to assess potency of viral vector particles Pending 22-Mar-2021 000000000
CA-3210581-A1 Methods of determining potency of a therapeutic cell composition Pending 22-Mar-2021 G01N33/505
To view Juno Therapeutics’s complete patent history, request access »

Juno Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Juno Therapeutics Former Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
ARCH Venture Partners Venture Capital Minority 000 0000 000000 0
Alaska Permanent Fund Sovereign Wealth Fund Minority 000 0000 000000 0
BB Biotech Asset Manager Minority 000 0000 000000 0
Bezos Expeditions Family Office Minority 000 0000 000000 0
Biomark Capital PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 19 investors. Get the full list »

Juno Therapeutics Investments & Acquisitions (10)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00 0000000000 03-Jun-2020 00000 0000 00000 Biotechnology 0000 0000
00 0000000000 20-Nov-2019 00000 0000 0000 Biotechnology
00 0000000000 09-May-2019 00000 0000 00000 Biotechnology
00 0000000000 24-May-2018 00000 0000 000.00 Biotechnology 0000 0000
RedoxTherapies 14-Jul-2016 Merger/Acquisition 0000 Pharmaceuticals 0000 0000
You’re viewing 5 of 10 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial

Juno Therapeutics Exits (5)

Company Name Exit Date Exit Type Exit Size Status Buyers
00 000000000000 03-Jun-2020 00000 00000 00 00000 Completed
  • 11 buyers
00 000000000000 20-Nov-2019 00000 00000 00 0000 Completed
  • 0000 000000000000
00 000000000000 09-May-2019 00000 00000 00 00000 Completed
  • 8 buyers
00 000000000000 24-May-2018 00000 00000 00 000.00 Completed
  • 9 buyers
JW Therapeutics 18-Feb-2016 Joint Venture Completed
  • 2 buyers
To view Juno Therapeutics’s complete exits history, request access »